Palex Medical SA has acquired Grupo Taper
Palex Medical SA, a leading distributor of medical equipment in Spain and Portugal, has acquired the healthcare business of Grupo Taper, with the objective to strengthen its position as a distributor company within the hospitality sector. Financial details have not been disclosed.
Founded in 1955, Palex Medical has three divisions: the hospital division that serves the needs of hospitals, clinics, medical centers and private practices; the lab and research division specializes in complete, integrated solutions for all types of anatomical pathology labs, research and diagnostic laboratories; and the specialty clinics division providing image diagnosis services.
Founded in 1989, Grupo Taper is a Spanish company that distributes equipment and products for medical centers, pathological anatomy labs, investigation and diagnosis for the food industry.
Oaklins' team in Spain advised the buyer in this transaction.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more